We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The role of sirolimus in the treatment of vascular anomalies.
- Authors
KOPEĆ, JAKUB; GAWŁOWSKA, ALEKSANDRA; KOPEĆ, EWA; PRZEWRATIL, PRZEMYSŁAW
- Abstract
Vascular anomalies are classified by the International Society for the Study of Vascular Anomalies (ISSVA). They result from an abnormal embryonic development of vessels, and in most cases, they are present at birth. A minority of VAs manifest at a later stage. They grow along with the child and may enlarge spontaneously during an infection. They often create aesthetic flaws, pain, impaired quality of life and require challenging treatment options that frequently do not provide patients with desired results. Part of these anomalies are classified as lymphatic. Proper diagnosis is based on radiological tests, including ultrasonography, computed tomography and magnetic resonance. It is vital to establish a correct diagnosis that precedes the appropriate treatment. The mammalian target of rapamycin (mTOR) inhibitor sirolimus is an effective treatment for difficult lymphatic anomalies. This article presents the current use of sirolimus and its antiproliferative properties that enables mTOR pathway inhibition, leading directly to stopping, reversing or minimising the effects of development of vascular anomalies. So far, it has been proven that sirolimus has a measurable effect on lymphatic malformations, is well tolerated, manageable and rarely produces adverse effects. Still, there are no guidelines for sirolimus care in patients with vascular anomalies as we lack prospective clinical trials.
- Subjects
RAPAMYCIN; MTOR inhibitors; BLOOD-vessel abnormalities; LYMPHATIC abnormalities; PHARMACODYNAMICS
- Publication
Family Medicine & Primary Care Review, 2022, Vol 24, Issue 2, p168
- ISSN
1734-3402
- Publication type
Article
- DOI
10.5114/fmpcr.2022.115879.